{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:24:38Z","timestamp":1769073878417,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970116"],"award-info":[{"award-number":["81970116"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.leukres.2022.106953","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T11:00:42Z","timestamp":1663412442000},"page":"106953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment"],"prefix":"10.1016","volume":"122","author":[{"given":"Chunhong","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuicui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106953_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.leukres.2022.106953_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.leukres.2022.106953_bib3","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2022.106953_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2119\/2006-00082.Stevenson","article-title":"CD38 as a therapeutic target","volume":"12","author":"Stevenson","year":"2006","journal-title":"Mol. Med."},{"key":"10.1016\/j.leukres.2022.106953_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imj.13707","article-title":"Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma","volume":"48","author":"Quach","year":"2018","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.leukres.2022.106953_bib6","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106953_bib7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \"don't eat me\" signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2022.106953_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/trf.15033","article-title":"Monoclonal anti-CD47 interference in red cell and platelet testing","volume":"59","author":"Velliquette","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.leukres.2022.106953_bib9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.leukres.2022.106953_bib10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.hoc.2019.05.007","article-title":"Impact of novel monoclonal antibody therapeutics on blood bank pretransfusion testing","volume":"33","author":"Mei","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2022.106953_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/tme.12664","article-title":"Two case reports involving therapeutic monoclonal anti-CD47 (Hu5F9-G4), it's effect on compatibility testing and subsequent selection of components for transfusion","volume":"30","author":"Reyland","year":"2020","journal-title":"Transfus. Med"},{"key":"10.1016\/j.leukres.2022.106953_bib12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/trf.14021","article-title":"Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.leukres.2022.106953_bib13","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.leukres.2022.106953_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.21307\/immunohematology-2019-025","article-title":"Dithiothreitol treatment of red blood cells","volume":"33","author":"Bub","year":"2017","journal-title":"Immunohematology"},{"key":"10.1016\/j.leukres.2022.106953_bib15","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.leukres.2022.106953_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1804751","article-title":"F(ab')2 fragments to overcome daratumumab interference in transfusion tests","volume":"379","author":"Selleng","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106953_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000495773","article-title":"Daratumumab interference in pretransfusion testing is overcome by addition of daratumumab fab fragments to Patients' plasma","volume":"46","author":"Werle","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.leukres.2022.106953_bib18","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/trf.15341","article-title":"Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma","volume":"59","author":"Yeh","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.leukres.2022.106953_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/16078454.2021.1918916","article-title":"2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests","volume":"26","author":"Zhou","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2022.106953_bib20","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1111\/trf.14900","article-title":"Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01\u2009mol\u2009L\u22121 dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)","volume":"58","author":"Hosokawa","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.leukres.2022.106953_bib21","first-page":"290","article-title":"New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing","volume":"18","author":"Izaguirre","year":"2020","journal-title":"Blood Transfus."},{"key":"10.1016\/j.leukres.2022.106953_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.leukres.2022.106953_bib23","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.leukres.2022.106953_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2141.2011.08843.x","article-title":"Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force","volume":"155","author":"Davies","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106953_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21307\/immunohematology-2020-008","article-title":"Inhibition of blood group antibodies by soluble substances","volume":"35","author":"Byrne","year":"2019","journal-title":"Immunohematology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:19Z","timestamp":1758934999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":25,"alternative-id":["S0145212622001795"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106953","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106953"}}